Literature DB >> 8053485

Detection and characterization of Epstein-Barr virus in clinical specimens.

R F Ambinder1, R B Mann.   

Abstract

Epstein-Barr virus (EBV) is associated with a wide spectrum of benign and malignant diseases. Recent additions to the list include oral hairy leukoplakia; a subset of Hodgkin's lymphomas, particularly those with mixed cellularity histology or those occurring in underdeveloped countries; a subset of diffuse large cell/immunoblastic lymphoma in the immunocompromised, particularly primary central nervous system lymphoma; a subset of peripheral T cell lymphomas; and a subset of gastric carcinomas, particularly undifferentiated carcinomas. There are several distinctive aspects of the biology of the virus that are important in investigations of virus in clinical specimens. The presence of repeated elements in the genome facilitates detection of viral nucleic acids by a variety of hybridization techniques as well as the characterization of the clonality of virus-infected tissues. Latent viral infection is associated with several different patterns of viral gene expression in infected cells. Latent gene products are important because of their growth-regulating and -transforming properties as well as the potent cytotoxic T cell response they elicit. The abundant expression of the EBER RNA transcripts makes possible the sensitive detection of latent infection in EBV-associated tumors. Lytic infection can be inhibited by antiviral nucleoside analogues. Two lytic gene products are of special interest because of their homology to the cellular proteins BCL-2 and interleukin-10. Two viral biotypes or strains with different properties in terms of lymphocyte immortalization and transformation have recently been characterized. Current evidence suggests a differential biotype association with particular malignancies. Characterization of the association of EBV with various disease processes promises to be important for diagnosis and treatment as well as for a better understanding of the epidemiology and pathogenesis of these diabetes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8053485      PMCID: PMC1887400     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  105 in total

1.  Concatameric replication of Epstein-Barr virus: structure of the termini in virus-producer and newly transformed cell lines.

Authors:  H Sato; T Takimoto; S Tanaka; J Tanaka; N Raab-Traub
Journal:  J Virol       Date:  1990-11       Impact factor: 5.103

2.  A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1.

Authors:  R Longnecker; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

3.  Detection of EBV gene expression in Reed-Sternberg cells of Hodgkin's disease.

Authors:  T C Wu; R B Mann; P Charache; S D Hayward; S Staal; B C Lambe; R F Ambinder
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

4.  Epstein-Barr virus small nuclear RNAs are not expressed in permissively infected cells in AIDS-associated leukoplakia.

Authors:  K Gilligan; P Rajadurai; L Resnick; N Raab-Traub
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

5.  EBNA size polymorphism can be used to trace Epstein-Barr virus spread within families.

Authors:  J W Gratama; M A Oosterveer; G Klein; I Ernberg
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

6.  Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.

Authors:  J Sample; L Young; B Martin; T Chatman; E Kieff; A Rickinson; E Kieff
Journal:  J Virol       Date:  1990-09       Impact factor: 5.103

7.  Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

Authors:  K W Moore; P Vieira; D F Fiorentino; M L Trounstine; T A Khan; T R Mosmann
Journal:  Science       Date:  1990-06-08       Impact factor: 47.728

8.  Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects.

Authors:  T B Sculley; A Apolloni; L Hurren; D J Moss; D A Cooper
Journal:  J Infect Dis       Date:  1990-09       Impact factor: 5.226

9.  High incidence of Epstein-Barr virus genomes in Hodgkin's disease.

Authors:  H Herbst; G Niedobitek; M Kneba; M Hummel; T Finn; I Anagnostopoulos; M Bergholz; G Krieger; H Stein
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

10.  Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man.

Authors:  M Rowe; L S Young; J Crocker; H Stokes; S Henderson; A B Rickinson
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

View more
  25 in total

1.  PY motifs of Epstein-Barr virus LMP2A regulate protein stability and phosphorylation of LMP2A-associated proteins.

Authors:  M Ikeda; A Ikeda; R Longnecker
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Poorly differentiated colonic adenocarcinoma, medullary type: clinical, phenotypic, and molecular characteristics.

Authors:  J Rüschoff; W Dietmaier; J Lüttges; G Seitz; T Bocker; H Zirngibl; J Schlegel; H K Schackert; K W Jauch; F Hofstaedter
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  RNAscope: a novel in situ RNA analysis platform for formalin-fixed, paraffin-embedded tissues.

Authors:  Fay Wang; John Flanagan; Nan Su; Li-Chong Wang; Son Bui; Allissa Nielson; Xingyong Wu; Hong-Thuy Vo; Xiao-Jun Ma; Yuling Luo
Journal:  J Mol Diagn       Date:  2012-01       Impact factor: 5.568

4.  Absence of Epstein-Barr virus in oesophageal squamous cell carcinoma.

Authors:  K Y Lam; G Srivastava; M L Leung; L Ma
Journal:  Clin Mol Pathol       Date:  1995-08

5.  Pleomorphic adenoma in the nasal cavity: a clinicopathological study of ten cases in Finland.

Authors:  S I Vento; J Numminen; I Kinnunen; M Rautiainen; J Tarkkanen; J Hagström; A A Mäkitie
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-04-07       Impact factor: 2.503

Review 6.  Adoptive immunotherapy for Epstein-Barr virus-associated lymphoproliferative disorders complicating marrow allografts.

Authors:  R J O'Reilly; T N Small; E Papadopoulos; K Lucas; J Lacerda; L Koulova
Journal:  Springer Semin Immunopathol       Date:  1998

7.  Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients.

Authors:  M A Nalesnik; A S Rao; A Zeevi; J J Fung; S Pham; H Furukawa; A Gritsch; G Klein; T E Starzl
Journal:  Transplant Proc       Date:  1997-05       Impact factor: 1.066

8.  Detection of Epstein-Barr virus in lower gastrointestinal tract lymphomas: a study in Malaysian patients.

Authors:  Asmah M Yunos; Hasnan Jaafar; Fauziah M Idris; Gurjeet Kaur; Mohamed J E M F Mabruk
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

9.  Detection of the Epstein-Barr virus in blood and bone marrow mononuclear cells of patients with aggressive B-cell non-Hodgkin's lymphoma is not associated with prognosis.

Authors:  Herlander Marques; Raquel Catarino; Nelson Domingues; Eliane Barros; Catarina Portela; Maria Inês Almeida; Sandra Costa; Rui Manuel Reis; Rui Medeiros; Adhemar Longatto-Filho
Journal:  Oncol Lett       Date:  2012-09-12       Impact factor: 2.967

10.  Virologic Diagnosis, Viral Monitoring, and Treatment of Epstein-Barr Virus Infectious Mononucleosis.

Authors:  Hal B. Jenson
Journal:  Curr Infect Dis Rep       Date:  2004-06       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.